Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | NOS1 | P29475 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.46 |
| ▸ | ATR | Q13535 | 1/20 | 0.43 |
| ▸ | GCK | P35557 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | RIOK2 | Q9BVS4 | 3/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21081212 | 0.89 | P2RX3 (0.44) | RAB9ANPC1SMN1; SMN2PKMP2RX3 | |
| SCHEMBL12888266 | 0.88 | P2RX3 (0.46) | RAB9ANPC1SMN1; SMN2PKMP2RX3 | |
| SCHEMBL23988616 | 0.87 | P2RX3 (0.45) | RAB9ANPC1SMN1; SMN2PKMP2RX3 | |
| SCHEMBL23988606 | 0.86 | P2RX3 (0.44) | RAB9ANPC1P2RX3ATRGCK | |
| SCHEMBL3938343 | 0.86 | RIOK2 (0.51) | RAB9ANPC1SMN1; SMN2PKMP2RX3 | |
| SCHEMBL30427105 | 0.86 | RIOK2 (0.51) | RAB9ANPC1SMN1; SMN2PKMP2RX3 | |
| SCHEMBL28810856 | 0.85 | ALDH1A1 (0.45) | SMN1; SMN2P2RX3ATRLMNAGSK3B | |
| SCHEMBL21999303 | 0.85 | P2RX3 (0.42) | RAB9ANPC1SMN1; SMN2PKMP2RX3 | |
| SCHEMBL25596870 | 0.84 | P2RX3 (0.41) | P2RX3ATRGCKGSK3BDYRK1A | |
| SCHEMBL25596869 | 0.83 | ELANE (0.44) | P2RX3ATRGCKGSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49699-E1 | Inhibitors of TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-10-17 | — | — | US | disclosed |
| CN-111527078-B | Pyridinecarbonyl derivatives and their therapeutic use as TRPC6 inhibitors | 勃林格殷格翰国际公司 | 2023-06-02 | — | — | CN | disclosed |
| EP-3700902-B1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INT (DE) | 2023-03-08 | — | — | EP | disclosed |
| EP-3786160-B1 | PYRIDINE DERIVATIVES AND THERAPEUTIC USES THEREOF AS TRPC6 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2022-07-13 | — | — | EP | disclosed |
| US-20210163449-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-06-03 | — | — | US | disclosed |
| EP-3786160-A1 | PYRIDINE DERIVATIVES AND THERAPEUTIC USES THEREOF AS TRPC6 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2021-03-03 | — | — | EP | disclosed |
| US-10889568-B2 | Inhibitors of TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-01-12 | — | — | US | disclosed |
| US-10800757-B2 | Inhibitors of TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-10-13 | — | — | US | disclosed |
| CN-111527078-A | Pyridinecarbonyl derivatives and their therapeutic use as TRPC6 inhibitors | 勃林格殷格翰国际公司 | 2020-08-11 | — | — | CN | disclosed |
| US-20190169168-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-06-06 | — | — | US | disclosed |
| US-20190169167-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169168-A1 | INHIBITORS OF TRPC6 | TRPC6, TRPC1, TRPC7 | RAB9A 558/4885NPC1 135/4885SMN1; SMN2 2918/4885 |
| US-20210163449-A1 | INHIBITORS OF TRPC6 | TRPC6, TRPC1, TRPC7 | RAB9A 497/4885NPC1 143/4885SMN1; SMN2 3310/4885 |
| US-10889568-B2 | Inhibitors of TRPC6 | TRPC6, TRPC1, TRPC7 | RAB9A 558/4885NPC1 135/4885SMN1; SMN2 2918/4885 |
| US-20190169167-A1 | INHIBITORS OF TRPC6 | TRPC6, TRPC1, TRPC7 | RAB9A 558/4885NPC1 135/4885SMN1; SMN2 2918/4885 |
| US-10800757-B2 | Inhibitors of TRPC6 | TRPC6, TRPC1, TRPC7 | RAB9A 558/4885NPC1 135/4885SMN1; SMN2 2918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.